Novartis Ag (NVS) Cost of Revenue (2016 - 2025)
Historic Cost of Revenue for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $3.6 billion.
- Novartis Ag's Cost of Revenue rose 863.42% to $3.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $13.7 billion, marking a year-over-year increase of 679.82%. This contributed to the annual value of $13.7 billion for FY2025, which is 679.82% up from last year.
- Novartis Ag's Cost of Revenue amounted to $3.6 billion in Q4 2025, which was up 863.42% from $3.5 billion recorded in Q3 2025.
- Novartis Ag's Cost of Revenue's 5-year high stood at $4.0 billion during Q1 2021, with a 5-year trough of $2.9 billion in Q3 2022.
- For the 5-year period, Novartis Ag's Cost of Revenue averaged around $3.4 billion, with its median value being $3.3 billion (2024).
- Per our database at Business Quant, Novartis Ag's Cost of Revenue surged by 1414.41% in 2021 and then tumbled by 2701.88% in 2022.
- Novartis Ag's Cost of Revenue (Quarter) stood at $4.0 billion in 2021, then decreased by 23.52% to $3.0 billion in 2022, then dropped by 0.62% to $3.0 billion in 2023, then increased by 9.99% to $3.3 billion in 2024, then rose by 8.63% to $3.6 billion in 2025.
- Its Cost of Revenue was $3.6 billion in Q4 2025, compared to $3.5 billion in Q3 2025 and $3.3 billion in Q2 2025.